Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Allergan CFO steps down amid buyout drama, but analysts aren't concerned

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Allergan CFO's departure may signal strength, not weakness

The sudden departure of a C-suite exec always raises eyebrows. When the company is a buyout target in the midst of a heated takeover battle, the questions really fly. But in the case of Allergan CFO Jeff Edwards, whose departure the company announced Monday, analysts say there's nothing to worry about.

Former Warner Chilcott CFO Paul Herendeen takes that spot at Zoetis

Paul Herendeen has been appointed as the new executive vice president and chief financial officer to Zoetis, the animal health industry leader. Reporting to CEO Juan Ramón Alaix, he will oversee the company's finance and IT segments.

Leading U.K. banker rumored for Glaxo chairman post

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Weber intends to build Takeda into a global player but stay true to its Japanese heritage

Takeda Pharmaceuticals' new French-born CEO knows he is seen as an outsider by many Japanese, including some of Takeda's alumni. He appreciates their concerns and says Takeda will remain a Japanese-based company, true to its heritage. But he also knows the man who hired him expects him to build the company into a global contender and says that is what he intends to do.

Former top Sanofi exec Whitaker nabbed by Synta to shuttle cancer drug to market

Less than a week after mysteriously leaving a prestigious post as president of Sanofi's North American pharma unit, Anne Whitaker has tackled a rather different challenge, accepting the CEO job at Synta Pharmaceuticals, a company that has struggled to get any drugs out of its pipeline since its founding 13 years ago.

FT sources: RBS' Hampton top contender to succeed Glaxo chair

A bribery scandal in China, with other probes ongoing in the Middle East and Europe. Mounting competition to declining top drug Advair. And so-far-lackluster launches of the products tabbed as future respiratory stars. So, who wants to be GlaxoSmithKline's next chairman?

Ex-Sanofi exec Whitaker takes the reins at Synta

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Exosome Diagnostics replaces CEO and relocates as it preps for commercialization

Exosome Diagnostics will advance its prostate cancer urine test to market with a new CEO and a change in locale to one of the biggest biotech clusters in the world.

Dendreon appoints ex-J&J exec as its new CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...